A detailed history of Principal Financial Group Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 93,208 shares of LGND stock, worth $10.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
93,208
Previous 88,769 5.0%
Holding current value
$10.4 Million
Previous $7.48 Million 24.83%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$82.7 - $110.11 $367,105 - $488,778
4,439 Added 5.0%
93,208 $9.34 Million
Q2 2024

Jul 29, 2024

SELL
$68.53 - $87.91 $229,918 - $294,938
-3,355 Reduced 3.64%
88,769 $7.48 Million
Q1 2024

Apr 29, 2024

SELL
$68.64 - $89.2 $47,087 - $61,191
-686 Reduced 0.74%
92,124 $6.73 Million
Q4 2023

Feb 07, 2024

SELL
$49.57 - $72.63 $62,854 - $92,094
-1,268 Reduced 1.35%
92,810 $6.63 Million
Q3 2023

Nov 02, 2023

SELL
$58.86 - $72.67 $234,380 - $289,371
-3,982 Reduced 4.06%
94,078 $5.64 Million
Q2 2023

Aug 07, 2023

SELL
$69.53 - $79.33 $251,003 - $286,381
-3,610 Reduced 3.55%
98,060 $7.07 Million
Q1 2023

May 09, 2023

SELL
$65.67 - $77.08 $124,707 - $146,374
-1,899 Reduced 1.83%
101,670 $7.48 Million
Q4 2022

Feb 09, 2023

BUY
$61.72 - $96.74 $76,841 - $120,441
1,245 Added 1.22%
103,569 $6.92 Million
Q3 2022

Nov 09, 2022

SELL
$0.01 - $107.56 $116 - $1.26 Million
-11,677 Reduced 10.24%
102,324 $8.81 Million
Q2 2022

Aug 10, 2022

SELL
$74.52 - $117.06 $627,085 - $985,059
-8,415 Reduced 6.87%
114,001 $10.2 Million
Q1 2022

May 09, 2022

SELL
$94.99 - $151.56 $811,499 - $1.29 Million
-8,543 Reduced 6.52%
122,416 $13.8 Million
Q4 2021

Feb 09, 2022

SELL
$127.69 - $165.85 $4.44 Million - $5.76 Million
-34,752 Reduced 20.97%
130,959 $20.2 Million
Q3 2021

Nov 09, 2021

BUY
$102.33 - $144.73 $5.72 Million - $8.09 Million
55,913 Added 50.92%
165,711 $23.1 Million
Q2 2021

Aug 10, 2021

BUY
$113.03 - $155.64 $993,420 - $1.37 Million
8,789 Added 8.7%
109,798 $14.4 Million
Q1 2021

May 10, 2021

BUY
$99.52 - $215.83 $1.24 Million - $2.69 Million
12,476 Added 14.09%
101,009 $15.4 Million
Q4 2020

Feb 08, 2021

SELL
$80.55 - $106.05 $848,594 - $1.12 Million
-10,535 Reduced 10.63%
88,533 $8.8 Million
Q3 2020

Nov 06, 2020

BUY
$89.56 - $126.72 $1.8 Million - $2.55 Million
20,104 Added 25.46%
99,068 $9.44 Million
Q2 2020

Aug 05, 2020

BUY
$68.28 - $123.65 $1.86 Million - $3.36 Million
27,209 Added 52.57%
78,964 $8.83 Million
Q1 2020

May 12, 2020

SELL
$63.37 - $107.88 $1.62 Million - $2.76 Million
-25,624 Reduced 33.11%
51,755 $3.76 Million
Q4 2019

Feb 05, 2020

SELL
$96.94 - $113.59 $330,177 - $386,887
-3,406 Reduced 4.22%
77,379 $8.07 Million
Q3 2019

Nov 13, 2019

SELL
$86.25 - $120.16 $348,881 - $486,047
-4,045 Reduced 4.77%
80,785 $8.04 Million
Q2 2019

Aug 12, 2019

SELL
$107.38 - $129.34 $689,164 - $830,104
-6,418 Reduced 7.03%
84,830 $9.68 Million
Q1 2019

May 10, 2019

SELL
$105.93 - $142.47 $317,472 - $426,982
-2,997 Reduced 3.18%
91,248 $11.5 Million
Q4 2018

Feb 14, 2019

SELL
$128.36 - $272.13 $12.1 Million - $25.7 Million
-94,407 Reduced 50.04%
94,245 $12.8 Million
Q3 2018

Nov 14, 2018

BUY
$211.18 - $274.49 $1.17 Million - $1.52 Million
5,528 Added 3.02%
188,652 $51.8 Million
Q2 2018

Aug 13, 2018

BUY
$150.77 - $207.98 $78,098 - $107,733
518 Added 0.28%
183,124 $0
Q1 2018

May 14, 2018

BUY
$138.63 - $182.62 $732,798 - $965,329
5,286 Added 2.98%
182,606 $30.2 Million
Q4 2017

Feb 13, 2018

BUY
$128.36 - $147.04 $2.02 Million - $2.31 Million
15,723 Added 9.73%
177,320 $24.3 Million
Q3 2017

Nov 02, 2017

BUY
$120.91 - $137.94 $19.5 Million - $22.3 Million
161,597
161,597 $22 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.